Preferred Label : Ibandronic Acid;

MeSH definition : Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.;

MeSH hyponym : 1-Hydroxy-3-(methylpentylamino)propylidenebisphosphonate; (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonate; Ibandronic Acid, Sodium Salt, Monohydrate; RPR-102289A; RPR102289A; BM 210955; BM-21.0955; BM21.0955; BM-210955; BM210955;

MeSH CAS label : Phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis-;

MeSH Related Number : 114084-78-5 (Ibandronic Acid); 23Y0B94E49; J12U072QL0;

Wikipedia link : https://en.wikipedia.org/wiki/Ibandronic acid;

UNII : UMD7G2653W;

Details


Main resources

You can consult :

Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.

https://www.has-sante.fr/jcms/p_3107632/fr/bondronat
2019
false
false
false
France
evaluation of the transparency committee
bondronat
Ibandronic Acid

---
http://www.has-sante.fr/portail/jcms/c_2038292/fr/bondronat
http://www.has-sante.fr/portail/jcms/c_1020505/bondronat
http://www.has-sante.fr/portail/jcms/c_400002/fr/bondronat-6-mg/6ml-solution-a-diluer-pour-perfusion-boite-de-1-et-boite-de-5
2015
false
true
false
France
French
evaluation of the transparency committee
ibandronic acid
insurance, health, reimbursement
treatment outcome
bone neoplasms
breast neoplasms
neoplasm metastasis
Pathologic Fracture
bone neoplasms
bone neoplasms
Pathologic fracture of bone at site of metastatic neoplasm (disorder)
bone density conservation agents
diphosphonates
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=68741283
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62236840
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=69662294
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
https://www.ema.europa.eu/medicines/human/EPAR/Ibandronic-acid-Accord
2012
United Kingdom
English
French
ibandronic acid
drug approval
europe
treatment outcome
summary of product characteristics
package leaflet
drug evaluation
syndication feed
infusions, intravenous
drugs, generic
bone neoplasms
breast neoplasms
neoplasm metastasis
fractures, bone
hypercalcemia
diphosphonates
diphosphonates
bone density conservation agents
bone density conservation agents
neoplasms
adult
aged
drug interactions
pregnancy
breast feeding
fertility
bone resorption
drug evaluation, preclinical
Ibandronic Acid
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60058830
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60032077
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=65260476
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66694073
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
https://www.ema.europa.eu/medicines/human/EPAR/Iasibon
2012
United Kingdom
French
English
syndication feed
diphosphonates
diphosphonates
diphosphonates
drug approval
treatment outcome
infusions, intravenous
administration, oral
drugs, generic
bone density conservation agents
bone density conservation agents
hypercalcemia
bone neoplasms
fractures, bone
breast neoplasms
neoplasm metastasis
ibandronic acid
drug interactions
drug evaluation, preclinical
summary of product characteristics
package leaflet
drug evaluation
Ibandronic Acid
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=64524784
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=67579729
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60216903
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62024403
2012
France
summary of product characteristics
package leaflet
tablets
Ibandronic Acid

---
This medicine is now withdrawn from use in the European Union.
https://www.ema.europa.eu/medicines/human/EPAR/bondenza-previously-ibandronic-acid-roche
2011
false
United Kingdom
English
French
syndication feed
Contraindications, Procedure
food-drug interactions
drug interactions
pregnancy
breast feeding
diphosphonates
bone density conservation agents
diphosphonates
bone density conservation agents
renal insufficiency
diphosphonates
bone density conservation agents
drug labeling
osteoporosis, postmenopausal
diphosphonates
diphosphonates
diphosphonates
bone density conservation agents
bone density conservation agents
bone density conservation agents
treatment outcome
drug evaluation
tablets
administration, oral
injections, intravenous
fractures, bone
diphosphonates
bone density conservation agents
adult
aged
diphosphonates
bone density conservation agents
drug evaluation, preclinical
drug approval
ibandronic acid
diphosphonates
drug evaluation
summary of product characteristics
package leaflet
Contraindications, Drug
Ibandronic Acid

---
https://www.ema.europa.eu/medicines/human/EPAR/Bonviva
2011
United Kingdom
French
English
syndication feed
osteoporosis, postmenopausal
diphosphonates
diphosphonates
bone density conservation agents
bone density conservation agents
treatment outcome
drug evaluation
drug approval
drug labeling
injections, intravenous
administration, oral
spinal fractures
drug interactions
ibandronic acid
diphosphonates
drug evaluation
summary of product characteristics
package leaflet
Ibandronic Acid
Ibandronic Acid

---
https://www.ema.europa.eu/medicines/human/EPAR/Bondronat
2011
United Kingdom
French
English
syndication feed
bone resorption
drug approval
drug labeling
fractures, spontaneous
neoplasm metastasis
infusions, intravenous
adult
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
diphosphonates
bone density conservation agents
hypercalcemia
breast neoplasms
bone neoplasms
diphosphonates
bone density conservation agents
treatment outcome
drug evaluation
ibandronic acid
diphosphonates
drug evaluation
summary of product characteristics
package leaflet
Ibandronic Acid
Ibandronic Acid

---
https://www.ema.europa.eu/medicines/human/EPAR/Ibandronic-acid-Sandoz
2011
United Kingdom
French
English
summary of product characteristics
package leaflet
drug evaluation
syndication feed
drug approval
treatment outcome
diphosphonates
diphosphonates
drugs, generic
administration, oral
bone density conservation agents
bone density conservation agents
bone neoplasms
fractures, bone
breast neoplasms
neoplasm metastasis
ibandronic acid
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Ibandronic Acid
Ibandronic Acid

---
https://www.ema.europa.eu/medicines/human/EPAR/Ibandronic-Acid-Teva
2011
United Kingdom
French
English
syndication feed
fractures, bone
drug approval
pregnancy
drug interactions
breast feeding
treatment outcome
drug evaluation, preclinical
ibandronic acid
bone neoplasms
diphosphonates
diphosphonates
administration, oral
bone density conservation agents
bone density conservation agents
drugs, generic
osteoporosis, postmenopausal
diphosphonates
package leaflet
summary of product characteristics
drug evaluation
Ibandronic Acid
Ibandronic Acid

---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-01/bonviva_-_ct-8848.pdf
http://www.has-sante.fr/portail/jcms/c_1032343/bonviva-acide-ibandronique-bisphosphonate
2010
France
French
administration, oral
injections
diphosphonates
bone density conservation agents
ibandronic acid
femoral neck fractures
insurance, health, reimbursement
osteoporosis, postmenopausal
treatment outcome
diphosphates
bone density conservation agents
spinal fractures
diphosphonates
diphosphonates
evaluation of the transparency committee
guidelines for drug use
Ibandronic Acid
Ibandronic Acid

---
http://www.lecrat.eu/?s=Acide+ibandronique
2009
France
drug information
pregnancy, high-risk
pregnancy, nos
teratogens
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=68419617
2008
France
French
diphosphonates
administration, oral
tablets
ibandronic acid
drug information
Ibandronic Acid

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63460631
2008
France
French
diphosphonates
pharmaceutical solutions
injections, intravenous
ibandronic acid
drug information
Ibandronic Acid

---
http://www.meddispar.fr/medicaments/3634857
2008
France
French
diphosphonates
legislation, drug
bone density conservation agents
drug prescriptions
continuity of patient care
drug monitoring
infusions, parenteral
ibandronic acid
drug information
Ibandronic Acid

---
http://www.has-sante.fr/portail/display.jsp?id=c_459746
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct_2272_bonviva_ang.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct032637.pdf
2006
France
French
English
diphosphonates
bone density conservation agents
insurance, health, reimbursement
tablets
osteoporosis, postmenopausal
spinal fractures
administration, oral
diphosphonates
bone density conservation agents
ibandronic acid
diphosphonates
evaluation of the transparency committee
Ibandronic Acid
Ibandronic Acid

---
http://www.has-sante.fr/portail/display.jsp?id=c_468572
2006
France
French
syringes
pharmaceutical solutions
diphosphonates
bone density conservation agents
injections, intravenous
osteoporosis, postmenopausal
spinal fractures
insurance, health, reimbursement
treatment outcome
bone density conservation agents
diphosphonates
ibandronic acid
diphosphonates
evaluation of the transparency committee
Ibandronic Acid
Ibandronic Acid

---
https://rmlg.uliege.be/article/1495
2006
Belgium
French
drug administration schedule
bone density conservation agents
diphosphonates
bone density conservation agents
osteoporosis, postmenopausal
medication adherence
diphosphonates
journal article
Ibandronic Acid

---
http://www.has-sante.fr/portail/display.jsp?id=c_400998
http://www.has-sante.fr/portail/upload/docs/application/pdf/ct_2781_bonviva_ang.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/bonviva.pdf
2006
France
French
English
tablets
diphosphonates
bone density conservation agents
administration, oral
insurance, health, reimbursement
osteoporosis, postmenopausal
spinal fractures
treatment outcome
ibandronic acid
diphosphonates
evaluation of the transparency committee
Ibandronic Acid

---
Nous contacter.
04/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.